Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
regn6569
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
REGN6569 is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that acts as an agonist of the glucocorticoid-induced tumor necrosis factor receptor (GITR; also known as TNFRSF18 or CD357). By targeting and activating GITR, REGN6569 modulates immune checkpoint pathways and enhances antitumor immune responses. The drug is being developed for the treatment of advanced solid tumors, including colorectal cancer and head and neck squamous cell carcinoma. It has been studied in combination with cemiplimab (an anti–PD-1 antibody), showing evidence of immune activation such as increased proliferating NK cells and full receptor occupancy on circulating regulatory T cells. REGN6569 is administered intravenously and was developed using Regeneron's VelociGene and VelocImmune platform technologies[1][2][7].
- Other names
- anti-GITR agonistic monoclonal antibody REGN6569
02
Targets
TNFRSF18 (GITR)
Beyond the preview
Go deeper on regn6569.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on regn6569.